Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display.
about
Monoclonal antibodies in acute lymphoblastic leukemiaIsolation of anti-CD22 Fv with high affinity by Fv display on human cells.In vitro antibody affinity maturation targeting germline hotspotsClass II human leucocyte antigen DRB1*11 in hairy cell leukaemia patients with and without haemolytic uraemic syndrome.Paclitaxel-loaded polymeric micelles modified with MCF-7 cell-specific phage protein: enhanced binding to target cancer cells and increased cytotoxicity.Affinity-matured anti-glycoprotein NMB recombinant immunotoxins targeting malignant gliomas and melanomas.Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trialImmunotherapy of childhood cancer: from biologic understanding to clinical application.Paclitaxel synergizes with exposure time adjusted CD22-targeting immunotoxins against B-cell malignancies.Cell membrane-specific epitopes on CD30: Potentially superior targets for immunotherapy.Bioengineering a unique deimmunized bispecific targeted toxin that simultaneously recognizes human CD22 and CD19 receptors in a mouse model of B-cell metastases.Antibody phage display libraries: contributions to oncology.Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes.Antiviral activity of a single-domain antibody immunotoxin binding to glycoprotein D of herpes simplex virus 2.A guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer.Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotoxTreatment of hematologic malignancies with immunotoxins and antibody-drug conjugates.The improvement of an anti-CD22 immunotoxin: conversion to single-chain and disulfide stabilized form and affinity maturation by alanine scanPhase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia.Immunoconjugates in the management of hairy cell leukemia.Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemiaEfficacy and toxicity of a CD22-targeted antibody-saporin conjugate in a xenograft model of non-Hodgkin's lymphomaA recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicityAnti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia.A modified form of diphthamide causes immunotoxin resistance in a lymphoma cell line with a deletion of the WDR85 gene.An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes.Soluble CD22 as a tumor marker for hairy cell leukemia.Protein Kinase Inhibitor H89 Enhances the Activity of Pseudomonas Exotoxin A-Based Immunotoxins.Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity.Linked-in: design and efficacy of antibody drug conjugates in oncologyHairy cell leukemia - immunotargets and therapiesA protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity.Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignanciesGenetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy.CAT-8015: a second-generation pseudomonas exotoxin A-based immunotherapy targeting CD22-expressing hematologic malignancies.A reevaluation of CD22 expression in human lung cancer.Immunotoxins for leukemia.Molecular engineering of antibodies for therapeutic and diagnostic purposes.Novel therapeutic strategies in adult acute lymphoblastic leukemia--a focus on emerging monoclonal antibodies.Novel antibody-based proteins for cancer immunotherapy.
P2860
Q27022540-8006185B-5934-4B31-A867-8C16B5F28F59Q33246226-F1A9324E-1783-478A-98A3-99AA1A0BD14BQ33413796-5C2E0229-6784-45DF-A051-8654C15495D4Q33415933-6FC6EFE6-A8E0-4B4D-AA50-D1CB56855FE8Q33592506-28D0DC52-DBD8-48F7-9644-FE3C498B6E7CQ33687487-6B178AD3-F9DB-486B-B1B2-85BDBEEA67B5Q33732575-13817C7D-BD9B-4843-9BFC-EE9A0FD8583CQ33752982-57CBA212-394C-47B3-8578-C6839B1A7425Q33761496-FE295001-0306-403A-89F3-B6A312710E66Q33841251-73B112C3-59A1-4CAB-8396-9E0021029411Q33907691-CC8DB386-1E4C-43F3-A767-DBD0346F7677Q34323991-1F063A7E-2F5D-433C-9C19-37FD74EC3B45Q34804520-7AD7B032-0928-4972-B098-FF5B6A206DCFQ34923432-4D91DD14-68D3-4825-8456-18666114811EQ35230663-205CB30D-3C6C-4650-8FBF-EE9ED0EC1291Q35446035-52F5AD67-18AA-421A-A071-327133E52FA6Q35446333-28299E42-0286-4322-A9D8-E30FE53EECB5Q35578041-3CA7076E-3336-4B08-BAFD-EEA1496AF8C8Q36058502-0BED3803-89F2-47A1-BEF6-C08F5B1E24F7Q36328016-3673D3E9-1AEA-44EA-99F9-C92DD2A1EA94Q36339717-50A8317B-675E-439A-A23C-85286819B045Q36476080-82998A20-5D83-496E-BED6-017621CE2975Q36536466-E4F7CE52-AD87-4604-8414-E2E21BA53A2CQ36619703-2141CAC5-0205-4F82-A1B4-C2BC617350EBQ36796947-D7AAFC4F-B075-42FE-AC75-39ABC734FEA5Q36837402-B23B6618-2691-4C76-9F99-2C5A2A26E4CCQ36868716-F212BB63-2F79-4DF0-99CE-F04F24259895Q36917916-7A2E601C-671C-4524-B2E8-04260E91AB4FQ36923799-49A6CDA0-6D2F-4AE2-AB06-1B56BEB9B656Q37029370-F9726ADD-7694-46C5-BEB9-AAF52F445DE9Q37031666-05782C99-E932-43FB-ABEC-0BA5211C475AQ37162862-BE5FA848-CBA0-4F55-8EC0-0F483EA06A24Q37165245-D39D1B32-671C-4DF7-BBB1-E3F0BE5D169DQ37334787-DB39E782-990A-43D4-832F-120517F4F9F0Q37342767-26B4F33E-963A-4A72-8FF1-19C2E67381A1Q37518988-03A0DCA9-52ED-4CEC-890F-909FE160E992Q37709336-1986A5D9-C258-456D-82A5-20465711082FQ38017581-101A1146-9917-48BD-AEB7-3F129556558AQ38094099-6C1684E8-6E78-445C-8700-41D47D0444E1Q38161370-01B23189-EFCD-433C-AD5B-5287AF9383D6
P2860
Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display.
description
2002 nî lūn-bûn
@nan
2002 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Improved cytotoxic activity to ...... ned by antibody phage display.
@ast
Improved cytotoxic activity to ...... ned by antibody phage display.
@en
type
label
Improved cytotoxic activity to ...... ned by antibody phage display.
@ast
Improved cytotoxic activity to ...... ned by antibody phage display.
@en
prefLabel
Improved cytotoxic activity to ...... ned by antibody phage display.
@ast
Improved cytotoxic activity to ...... ned by antibody phage display.
@en
P2093
P921
P1476
Improved cytotoxic activity to ...... ined by antibody phage display
@en
P2093
Giuliana Salvatore
Inger Margulies
Ira Pastan
Richard Beers
Robert J Kreitman
P304
P407
P577
2002-04-01T00:00:00Z